Business
Know the Business
Figures converted from Japanese yen at historical FX rates — see data/company.json.fx_rates for the rate table. Ratios, margins, and multiples are unitless and unchanged.
Tazmo is a $292M-market-cap Japanese niche equipment maker whose value depends on one decision: how to underwrite the mix shift inside Process Equipment from legacy single-wafer cleaning and FPD coaters toward temporary wafer bonders for AI-era advanced packaging. The economic engine is good (step-monopoly Japanese specialist, 14% ROE through cycle, net cash) but not great (small scale, no recurring services tail, customer-concentrated capital sales). The market's confusion is treating FY2026 guidance (operating profit -24.5%) as the new run-rate when it is the transition cost of replacing two legacy product lines with three early-stage ones (TBDB, LAB, DTB) priced for chiplet-era packaging.
FY2025 revenue ($M)
Operating margin
ROE
Free cash flow ($M)
Market cap ($M)
Net cash ($M)
P/E (TTM)
Operating income ($M)
1. How This Business Actually Works
Tazmo sells lumpy capital equipment that costs $0.6M–$6M per unit and ships in batches when a customer commissions a fab or a packaging line. There is no meaningful recurring service revenue — when shipments pause, revenue pauses. Three segments, but only one matters for the equity story: Process Equipment is 78% of group sales and 86% of segment profit, and inside it four product lines on entirely different cycles drive the result.
The economic engine in one sentence. Gross margin is set by what fraction of the ~$175M Process Equipment line is high-spec advanced-packaging tools vs. commodity transfer robots and recipe-led cleaning — when the mix tilts to bonder/debonder + slit coater + cleaning, GM is 33%+ and operating leverage runs to 16% (FY2024). When semiconductor equipment displaces cleaning at a lower per-unit margin, GM falls to 30% and operating leverage halves (FY2025: 13.5%; FY2026E: 10.1%).
R&D intensity is only 2% of sales — Tazmo does not invent the process, it engineers Japanese-precision tools for a step someone else specifies. SG&A is heavier (17% of sales), reflecting field-service infrastructure for a Japan-and-China-heavy installed base. Capex runs at ~3-4% of sales ($9.4M FY2025, guided $43.9M for FY2026 to build the Ibara demonstration plant and TAZMO Vietnam capacity). The balance sheet carries a structural overhang of work-in-process inventory ($74.4M end-FY2025, down from $101.1M) because each tool sits on the line for months awaiting customer inspection.
2. The Playing Field
Tazmo is the smallest public specialist in the Japanese semiconductor-equipment cluster — roughly 1/15th the revenue of SCREEN, 1/13th the revenue of DISCO, 1/68th the revenue of TEL — and the only one that pairs a bonder/debonder franchise with an FPD slit-coater heritage. The right peer set is SUSS MicroTec (direct bonder competitor, similar size), SCREEN (cleaning + FPD overlap), DISCO (advanced-packaging adjacency), TEL (coater/developer bellwether), and EBARA (PCB plating overlap). What this peer set reveals is that "good" in this industry is operating margins above 20% and ROE above 20% — and only the three companies with a clear step-monopoly (DISCO grinding/dicing, TEL coater/developer track, SCREEN single-wafer cleaning) get there. SUSS and Tazmo are stuck in the 12-14% margin band where two or three vendors compete for each step.
Two reads from the chart. First, Tazmo and SUSS occupy the same productivity band (op margin 12-14%, ROE mid-teens) — they are the right valuation reference, not DISCO or TEL. SUSS trades at 37x trailing P/E to Tazmo's 13x, a gap wider than scale alone explains; it reflects credit for SUSS's hybrid-bonding pipeline that Tazmo has not yet earned. Second, the step-monopoly cluster (DISCO, TEL, SCREEN) is what Tazmo cannot become without dominant share in one process step — its slit-coater dominance is in a maturing market (LCD color filter) too small to lift the consolidated numbers. The setup is not for a TEL multiple; it is whether the SUSS multiple, applied to a cleaner Tazmo franchise mix, supports a 2-3x upside on multiple convergence alone — with no margin expansion required.
3. Is This Business Cyclical?
Deeply cyclical, with the cycle hitting order intake first, mix second, margin third, working capital fourth. The decade chart makes the operating-leverage profile obvious: revenue swung from $167.6M (FY2019) to $228.5M (FY2024) — barely a 36% lift — while operating margin moved from 5.2% to 16.5%. The same operating leverage works in reverse: FY2025 revenue fell only -1.2% but operating profit fell -19.4% and FY2026E guidance is -24.5% on flat revenue.
The backlog chart is the single most informative cycle indicator for this company. Backlog peaked at $281M in Q1 FY2023, three quarters before revenue peaked in FY2024 at $228.5M. It has fallen for seven consecutive quarters to $125M at end-FY2025 — a clean read on the 2024-26 downturn even as headline revenue stayed near peak. The Q1 FY2026 print confirmed the pattern: revenue -20.6% YoY and operating profit -92.9% on the mix swing into early-stage advanced packaging at margins below the legacy cleaning equipment it displaced.
What the cycle taught in recent history. In FY2019, revenue fell 4.3% but operating profit fell 41% — the same operating-leverage profile as the FY2024-FY2026E down-cycle. The recovery from FY2019 to FY2024 took roughly five years of compounding capital orders. The FY2025-26 trough is shallower because advanced-packaging demand has held up; the FY2026E -24.5% operating-profit guide is the bull case for a mid-cycle pause, not a 2019-style downturn.
4. The Metrics That Actually Matter
Three of these six are non-obvious. Order backlog matters more than orders received, because new orders alone don't tell you whether revenue is being built or burned. Semi-equipment mix percentage matters because the consolidated GM is hostage to a single ratio that management discloses every quarter. Work-in-process inventory is a cash-flow predictor: when it spiked to $101.1M in FY2024, it set up the $50.6M FCF print in FY2025 as customers accepted backlog. Cash conversion of net income is over 200% on a trailing basis because the inventory builds and releases on a 12-18 month lag — that is the cash-cycle signature of a niche capital-equipment maker, not a sustainable margin profile.
What is NOT a useful metric here. Book-to-bill on a single quarter is too noisy (one large order swings it). Revenue growth in any quarter under 15% is inside noise. R&D-to-sales is not a quality signal at a Tazmo-scale specialist — the absolute R&D budget ($4.7M in FY2025) is what funds the LAB and DTB tools that matter, and the company is guiding it to $7.5M in FY2026 (+64%). That is the metric to watch, not the percentage.
5. What Is This Business Worth?
The right lens for Tazmo is normalized through-cycle EV/EBIT plus a margin-quality discount, not P/E on trailing or guidance numbers. Trailing P/E of 13x looks cheap; guided FY2026 P/E of 18.7x looks expensive — both miss that this is a single economic engine (Japanese niche specialist) whose normalized operating margin sits between FY2025's 13.5% and FY2024's 16.5%, call it 14%, on a normalized revenue base of $220-240M. That is $31-33M of normalized operating profit, or ~$22M net income, against a market cap of $292M and net cash of $53M. Enterprise value over normalized EBIT lands at 7-8x. SUSS MicroTec trades at ~24x EV/EBIT on a similar margin profile.
A sum-of-the-parts construction is not the right lens here. The three reportable segments are run as one business, the Mold & Resin segment is immaterial, Surface Treatment is too cyclical to value separately at a meaningful premium, and Tazmo has no listed subsidiaries or material investment stakes. The interesting decomposition is inside Process Equipment — between the legacy book (transfer + cleaning + remnant coater = $65M of FY2025 sales at low single-digit standalone margins) and the advanced-packaging book (semi equipment + folded coater = $115M+ of FY2025 sales at mid-teens margins growing 30%+). The legacy book is worth perhaps 0.8x sales ($52M); the advanced-packaging book at SUSS's ~2.0x sales multiple is worth $230M; Surface Treatment at 1.0x $43M sales = $43M; Mold & Resin at 0.5x $7.6M = $4M. Add net cash of $53M and the rough decomposition lands above current market cap, with the entire spread riding on the credit you give the advanced-packaging book.
What would make this cheap or expensive. Cheap: FY2026 H2 backlog stabilises near $130M and semi-equipment-as-percent-of-Process-Equipment crosses 65%, validating that the mix shift is structural and the FY2026 margin compression is transitional. Expensive: FY2026 backlog falls below $95M, LAB/DTB shipments slip into FY2027, or the new Ibara plant and Vietnam capex ($44M FY2026) front-runs demand that does not arrive — that would push net cash down and operating margin into single digits for a second year, breaking the through-cycle thesis.
6. What I'd Tell a Young Analyst
Don't anchor on FY2026 guidance. The 24.5% operating-profit drop is mathematically a mix problem, not a demand problem — advanced-packaging revenue is replacing cleaning revenue at a lower per-unit margin while the LAB and DTB ramps absorb engineering hours that get expensed as R&D. The same mechanic produced the 2019 trough that preceded the 2024 peak.
Watch the three things management has put dates on: first LAB unit sale in early 2026, DTB demo unit completion in FY2026, DTB mass production in 2027. If those slip, the multiple stays at 13x and the FY2026 margin compression turns into a re-rating to small-cap specialist territory (8-10x). If they hit, the bonder/debonder franchise compounds into the chiplet era and the SUSS-comparable multiple comes into reach.
Don't be fooled by the headline 1.06% dividend yield. The capital story is the $53M net cash position (18% of market cap), the $3.3M maiden buyback in FY2025, and the FY2026 capex guidance of $44M — which is what management would not be approving if they thought the AI-packaging cycle was ending. That capex is the most informative piece of management commentary in the FY2025 release.
Treat SUSS MicroTec as the index. When SUSS earnings beat, Tazmo's bonder franchise is implicitly being credited; when SUSS guides down, Tazmo's growth thesis is at risk regardless of what Tazmo reports. The two companies sell adjacent tools into the same customer queue.
The market may be underestimating the structural Japanese-specialist advantage in a post-export-control world and overestimating the FY2026 margin compression as permanent. The right question to ask each quarter is not "what did earnings do?" — it is "what did backlog do, and is the semi-equipment share of Process Equipment rising?"